For help on how to get the results you want, see our search tips.
954 results
Categories
Human Remove Human filter
Medicine
Paediatric investigation plans Remove Paediatric investigation plans filter
Withdrawn applications Remove Withdrawn applications filter
PIP decision type
RPM: decision refers to a refusal on the application for modification of an agreed PIP Remove RPM: decision refers to a refusal on the application for modification of an agreed PIP filter
W: decision granting a waiver in all age groups for all conditions or indications Remove W: decision granting a waiver in all age groups for all conditions or indications filter
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Levothyroxine (sodium)
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-002259-PIP01-17, Route(s) of administration: Oral use, Pharmaceutical form(s): Oral solution
Decision date: 16/03/2018, Last updated: 29/07/2020, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Aciclovir
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Infectious diseases
PIP number: EMEA-001066-PIP02-11-M03, Route(s) of administration: Gingival use, Pharmaceutical form(s): Muco-adhesive buccal tablet
Decision date: 04/12/2019, Last updated: 01/04/2020, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Daklinza, Daclatasvir
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Infectious diseases
PIP number: EMEA-001191-PIP01-11-M03, Route(s) of administration: Oral use, Pharmaceutical form(s): Chewable tablet, Film-coated tablet
Decision date: 08/11/2019, Last updated: 30/03/2020, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Influenza virus surface antigens (haemagglutinin) of strain A (H1N1), influenza virus surface antigens (haemagglutinin) of strain A (H3N2), influenza virus surface antigens (haemagglutinin) of strain B (Victoria lineage), influenza virus surface antigens (haemagglutinin) of strain B (Yamagata lineage)
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Infectious diseases
PIP number: EMEA-002027-PIP02-17-M01, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Suspension for injection
Decision date: 10/09/2019, Last updated: 26/03/2020, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Betmiga, Mirabegron
Decision type: RPM: decision refers to a refusal on the application for modification of an agreed PIP
Therapeutic area: Uro-nephrology
PIP number: EMEA-000597-PIP02-10-M07, Route(s) of administration: Oral use, Pharmaceutical form(s): Polonged-release granules for oral suspension, Prolonged-release tablet
Decision date: 30/09/2019, Last updated: 26/03/2020, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Revolade, Eltrombopag
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-000170-PIP02-10-M03, Route(s) of administration: Oral use, Pharmaceutical form(s): Powder for oral suspension, Film-coated tablet
Decision date: 22/03/2019, Last updated: 20/06/2019, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): phenylephrine hydrochloride, ketorolac trometamol (OMS302)
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Ophthalmology
PIP number: EMEA-001256-PIP02-12-M02, Route(s) of administration: Intraocular use, Ocular use, Pharmaceutical form(s): Concentrate for solution for injection, Irrigation solution
Decision date: 07/12/2018, Last updated: 19/02/2019, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Cimzia, Certolizumab pegol
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Dermatology
PIP number: EMEA-001071-PIP03-14-M01, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 07/12/2018, Last updated: 18/02/2019, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): levofloxacin, dexamethasone
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Ophthalmology
PIP number: EMEA-002375-PIP01-18, Route(s) of administration: Ocular use, Pharmaceutical form(s): Eye drops, solution in single-dose container
Decision date: 12/09/2018, Last updated: 12/02/2019, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Eviplera, emtricitabine, rilpivirine hydrochloride, tenofovir disoproxil fumarate
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Infectious diseases
PIP number: EMEA-000774-PIP01-09-M03, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 23/08/2018, Last updated: 05/02/2019, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Olysio, simeprevir
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Infectious diseases
PIP number: EMEA-000625-PIP01-09-M03, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard, Age-appropriate dosage form, other
Decision date: 12/09/2018, Last updated: 05/02/2019, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Trobalt, retigabine
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Neurology
PIP number: EMEA-000116-PIP01-07-M09, Route(s) of administration: Oral use, Intravenous use, Pharmaceutical form(s): Film-coated tablet, Dispersible tablet, Powder for solution for injection, Powder for solution for infusion, Chewable tablet
Decision date: 12/09/2018, Last updated: 30/01/2019, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Zydelig, Idelalisib
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-001350-PIP02-13-M04, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate dispersible tablet
Decision date: 09/11/2018, Last updated: 28/01/2019, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Pixuvri, pixantrone dimaleate
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-000713-PIP02-10-M05, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for concentrate for solution for infusion
Decision date: 20/07/2018, Last updated: 28/11/2018, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Adenuric, febuxostat
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-001417-PIP01-12-M04, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 20/07/2018, Last updated: 22/11/2018, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Ophthalmology
PIP number: EMEA-001039-PIP03-17, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Powder for solution for injection
Decision date: 13/04/2018, Last updated: 26/07/2018, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Ezetimibe, Rosuvastatin
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-001344-PIP02-17, Route(s) of administration: Oral use, Pharmaceutical form(s): Tablet
Decision date: 11/04/2018, Last updated: 26/07/2018, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): polatuzumab vedotin
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-002255-PIP01-17, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Concentrate for solution for infusion
Decision date: 11/04/2018, Last updated: 25/07/2018, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Rovalpituzumab tesirine
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-002292-PIP01-17, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder and solvent for concentrate for solution for infusion
Decision date: 11/04/2018, Last updated: 25/07/2018, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Calcium, N,N'-1,2-ethanediylbis[N-[[3-(hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methyl]glycine] manganese complexes
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-002293-PIP01-17, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Solution for infusion
Decision date: 11/04/2018, Last updated: 25/07/2018, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Enfortumab vedotin
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-002299-PIP01-17, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder and solvent for solution for infusion
Decision date: 11/04/2018, Last updated: 25/07/2018, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Trazodone (hydrochloride), gabapentin
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Pain
PIP number: EMEA-002263-PIP01-17, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard
Decision date: 16/03/2018, Last updated: 19/06/2018, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): dapagliflozin, metformin hydrochloride
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-001151-PIP02-17, Route(s) of administration: Oral use, Pharmaceutical form(s): Modified-release tablet
Decision date: 16/03/2018, Last updated: 19/06/2018, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Ibuprofen
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Other
PIP number: EMEA-002302-PIP01-17, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Solution for infusion
Decision date: 16/03/2018, Last updated: 19/06/2018, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Entinostat Polymorph B
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-002272-PIP01-17, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 16/03/2018, Last updated: 19/06/2018, Compliance check: X